Windtree Therapeutics (NASDAQ:WINT) Posts Earnings Results, Misses Expectations By $12.80 EPS

Windtree Therapeutics (NASDAQ:WINT) posted its quarterly earnings results on Monday. The company reported ($20.91) earnings per share for the quarter, missing the consensus estimate of ($8.11) by ($12.80), Zacks reports.

Windtree Therapeutics Trading Up 2.0 %

NASDAQ WINT opened at $11.22 on Wednesday. Windtree Therapeutics has a 12 month low of $2.81 and a 12 month high of $27.00. The stock’s fifty day moving average price is $5.81 and its 200-day moving average price is $5.71. The stock has a market cap of $6.64 million, a P/E ratio of -0.31 and a beta of 0.55.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product is istaroxime which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.